Plus   Neg

Lipocine Inc. (LPCN) Is Sinking After FDA Votes Against TLANDO

Lipocine Inc. (LPCN) announced after the close Wednesday that its New Drug Application for its oral testosterone product candidate TLANDO has failed to win support from an advisory committee to FDA.

Lipocine has gapped open sharply lower Thursday morning and is now down 1.73 at $1.73 on above average volume. The stock has plunged to a new low for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT